Drugs / CPO102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05043987 | Nov 2022 | gastric cancer, malignant pancreatic neoplasm | Conjupro Biotherapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPO102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05043987 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT05043987 ↗ |